X
Everything we have picked from this writer, newest first.
CFO change and rapid insider selling at $CACC ....could not begin to understand why the stock is up 20% in the past two weeks and nearly 50% ytd. Tougher float dynamics then you would want to see for a short but sure is tempting up here
crazy moves both directions over the past month away from AI... $GOLF +30% has got my attention. 30x next years numbers for a low single digit retailer seems odd.
@jonathanmaze Thanks for the insight! I don't live near a Caseys so could not conduct my own taste test but was overlaying wingstop locations on top of Caseys yesterday thinking this could be a growing problem for $WING especially undercut on $
Travel, housing, biotech and waste stocks rallied while Amazon lagged after weak Prime sales, leaving Target, KB Home and Expedia moves hard to explain.
MetLife, Lincoln and regional banks including Western Alliance face interconnected private-credit exposure, with scrutiny of loan credit ratings.
Wabash's $WNC rally reflects hopes for a replacement trailer market in 2027 and tariffs on Chinese suppliers, despite cyclical balance-sheet risk.
Little perplexed you get more negative redemption stories around private credit, and the market only sells off the the the pure play PE companies. First derivatives are up? $MFC $FG $MET $WAL all have sizable exposure to the same asset class.....
Almost a 40% spread opened up since the beginning of June (3 weeks ago!) between $MSFT and $SOXX Nearly 60% on $CRM and $SOXX... Buckle up
FIS is framed as a deep-value payments opportunity amid an anticipated rotation out of semiconductor and mega-cap AI momentum names.
Netflix's 200-day support sits near $70, with hosting costs and World Cup viewership pressure driving near-term negative momentum.
Micron and Sandisk rely on large-cap tech’s rising equity, creating a circular spending trade vulnerable to capex cuts.
Butterfly Network faces questions over Midjourney’s 50,000-unit ultrasound plan, whose pool-based body-composition spas cannot replace CT or MRI diagnostics and may carry heavy maintenance and capital costs.
CarMax cut vehicle prices to lift sales, but lower gross profit, weak auto loans and Carvana competition leave significant challenges after earnings.
Boston Scientific's revenue doubled and EBIT rose from $1.4 billion to $4.1 billion over five years, while Farapulse and Watchman growth slows and valuation embeds substantial expectations.
Software sold off as private-credit names MFC, ARES and FG rose alongside banks, with JPM up 14% in June. The valuation gap points to lower private-credit prices.
ELF, CAVA, Shake Shack and Birkenstock surged 30% to 60% within weeks despite weak sales or lower outlooks, raising questions about rate, oil and short-squeeze driven retail rallies.
SLP’s buyout follows years of value destruction from expensive acquisitions, service-heavy revenue and collapsing free cash flow. Its FDA-used simulation software remains the core asset for private equity.
Dutch Bros has risen nearly 40% despite premium valuation as 7 Brew, Starbucks, McDonald’s, Dunkin and Swig intensify pricing pressure in refreshers and energy drinks.
$BIRK misses earnings, stock drops and now with one $250m repurchase the stock has squeezed up 70% in less than a month....
CAVA rose 30% in a week without news as Target and private-credit-exposed Ares also made sharp late-week moves.
Magnite faces questions over its CFO departure, insider selling and AI risks outside connected TV as its ad-tech position consolidates.
QXO’s pro forma capitalization is estimated at 1.1 billion shares and $8 billion of net debt after Kodiak, Beacon and TopBuild financing.
Eli Lilly’s NLRP3 trials put it alongside Novo Nordisk, while AstraZeneca and smaller developers add to obesity-drug competition.
forgot the ticker - de jour fraud is $INHD
